Pricing Log in Create free account

Cogent Biosciences, Inc. (COGT) vs Erasca, Inc. (ERAS)

Cogent Biosciences, Inc. and Erasca, Inc. are both Biotechnology companies. Cogent Biosciences, Inc. is the larger, with a market value of $5.1B against $4.6B — 1.1× the size. Across the 10 metrics below, Erasca, Inc. leads on 7 and Cogent Biosciences, Inc. on 3.

Valuation

Metric COGT ERAS Biotechnology median
P/E n/m n/m 10.60
P/S 233.33 n/m 9.40
P/B 11.56 12.34 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 208.77 n/m 9.02
Earnings yield (6.84%) (6.62%) (32.88%)
Free cash flow yield (5.72%) (5.65%) (23.13%)

Profitability

Metric COGT ERAS Biotechnology median
Gross margin 0.00% 0.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (146.55%) (78.25%) (51.96%)
Return on assets (68.00%) (65.25%) (46.06%)
Return on invested capital 0.00% (203.13%) 0.00%

Growth

Metric COGT ERAS Biotechnology median
Revenue growth (TTM) 110.23% — 6.76%
EPS growth (last fiscal year) (11.34%) 36.23% 29.88%
Revenue growth, 5-year CAGR 21.39% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric COGT ERAS Biotechnology median
Debt to equity 0.42 0.00 0.00
Current ratio 13.57 8.29 4.97
Net debt to EBITDA 2.04 1.93 1.01

Dividend

Metric COGT ERAS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric COGT ERAS Biotechnology median
Market cap 5.13b 4.64b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack